Please assess the completion status of the following clinical trial:

Trial Title: Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and the willingness to sign a written informed consent document~* Histologically or cytologically confirmed stage IV squamous cell carcinoma of the oral cavity or oropharynx staged according to AJCC guidelines~* T4 staged tumor with a tumor volume greater than or equal to 30 cc~* Nodal staging of N0 through 2a~* No evidence of distant metastatic disease, as determined by a negative PET scan or other clinically appropriate means~* Age ≥ 18~* Clinically eligible for both intra-arterial and intravenous administration of cisplatin~* Women of childbearing potential must have a negative pregnancy test.~* Agree to use adequate contraception prior to study entry and for the duration of study participation and for 3 months after study treatment ended~* Biopsiable via a transoral approach~* Life expectancy of at least 5 years~* ECOG performance status ≤ 2~* Measurable disease as defined by RECIST criteria~* Absolute neutrophil count ≥ 1,000/mm3~* Hemoglobin ≥ 8.0 g/dl~* Platelet count ≥ 100,000/mm3~* Leukocytes≥3500/mcL~* Total Bilirubin ≤ ULN of institution performing testing~* Creatinine within normal institutional limits~Exclusion Criteria:~* Radiologic evidence of bone destruction~* Tumor with involvement of cartilage or bone~* Requires bilateral IA infusion with radiologist determination that tumor extends across the midline in excess of 30% of the tumor volume~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents and pre-medications used in the study, including drugs formulated with polysorbate 80~* Allergy to cardiac catheterization contrast agents, in which antihistamines are not sufficient to suppress a reaction or severe enough to pose a significant danger to the subject~* History of stroke, CABG, or significant blockage of carotid arteries or coronary arteries or current blockage of coronary or carotid arteries equal to or in excess of 50% blockage; Interventional radiology must agree that the patient is a good candidate for catheterization.~* Intolerance to IV, IA, or radiation therapy treatment for any reason as determined by the procedural physician~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnancy~* Breast feeding women~* Prior or concurrent non-head and neck malignancies, excluding adequately treated basal or squamous cell cancer of the skin, in situ cervical cancer, stage I or II cancer from which the subject has been in complete remission for at least 12 months, any cancer from which the subject has been cancer free for 5 years~* Tumor site which cannot provide a biopsy in the clinic via punch or core needle biopsy performed~* Second primary head and neck tumor (concurrent or previous head and neck tumor unless it was a basal or squamous cell skin cancer)~* Unknown primary tumor site~* Prior surgery, chemotherapy, biologic or radiotherapy for a head or neck malignancy (excluding minor surgical procedures for skin cancer)~* History of surgery (non-oncologic) in the field of the tumor or treatment bed.~* Participation in an investigational treatment or intervention study within 90 days of screening visit~* calculated creatinine clearance less than 60 mL/min/1.73 m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-arterial cisplatin and radiation (Type: EXPERIMENTAL): 150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
- Intravenous cisplatin and radiation (Type: ACTIVE_COMPARATOR): 100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues